STUDY OF CLINICAL AND NEUROHUMORAL PARAMETERS IN PATIENTS WITH THYROTOXICOSIS WITH COMORRIDITY WITH CHRONIC HEART FAILURE
Keywords:
thyrotoxicosis, chronic heart failure, comorbidityAbstract
The clinical and neurohumoral features of thyrotoxicosis comorbidity in patients with chronic heart failure were studied. The patients with FC II, medium-high levels of BNP prevailed, while in patients with FC III, a predominance of high levels of BNP was noted. Intermediate and high levels of BNP predominated in patients with FC II, while high levels of BNP predominated in patients with FC III. Based on the data obtained, a program was developed to determine the prognosis of the course of the disease in patients with thyrotoxicosis with comorbidity of CHF. At the same time, indicators of the clinical course of morbidity, hormone levels and BNP indicators.
Thus, in patients with thyrotoxicosis, comorbidity with CHF II with FC II, medium-high levels of BNP prevailed, while in patients with III FC there was a predominance of high levels of BNP, which correlated with the severity of the course of the disease and indicators of FV LV.
References
Рекомендации ESC по диагностике и лечению острой и хронической сердечной недостаточности 2016. Российский кардиологический журнал, 2017; 1 (141): 1-81.
Российское кардиологическое общество. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083
Фадеев В.В. По материалам клинических рекомендаций Европейской Тиреоидной Ассоциации по диагностике и лечению тиреотоксикоза при болезни Грейвса 2018 года. Клиническая и экспериментальная тиреоидология. 2020;16(1):4-20.
Чаулин А.М., Дупляков Д.В. Повышение натрийуретических пептидов, не ассоциированное с сердечной недостаточностью. Российский кардиологический журнал. 2020;25(4S):4140.
Branca L, Sbolli M, Metra M, Fudim M. Heart failure with mid-range ejection fraction: pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines. ESC Heart Fail. 2020 Apr;7(2):381-399.
Blick C, Nguyen M, Jialal I. Thyrotoxicosis. 2022 Jul 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 29489233.
Castiglione V, Aimo A, Vergaro G, Saccaro L, Passino C, Emdin M. Biomarkers for the diagnosis and management of heart failure. Heart Fail Rev. 2021 Apr 14. doi: 10.1007/s10741-021-101
De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016 Aug 27;388(10047):906-918. doi: 10.1016/S0140-6736(16)00278-6.
De Vecchis R., Esposito C., Di Biase G. et al. B-type natriuretic peptide-guided versus symptom-guided therapy in outpatients with chronic heart failure: a systematic review with meta-analysis. J Cardiovasc Med (Hagerstown), 2014; 15: 122–134.
Gheorghiade M., Vaduganathan M., Fonarow G. et al. Rehospitalization for Heart Failure Problems and Perspectives. J Am Coll Cardiol, 2013; 614: 391-403.
Mahmood S.S., Levy D., Vasan R.S., Wang T.J. The Framingham Heart Study and the Epidemiology of Cardiovascular Diseases: A Historical Perspective. Lancet, 2014; 383(9921): 999–1008.
McCulloch B. High-Output Heart Failure Caused by Thyrotoxicosis and Beriberi. Crit Care Nurs Clin North Am. 2015 Dec;27(4):499-510.
Ontario Health (Quality). Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as Diagnostic Tests in Adults With Suspected Heart Failure: A Health Technology Assessment. Ont Health Technol Assess Ser. 2021 May 6;21(2):1-125.
Suzuki S, Sugiyama S. The Molar Ratio of N-terminal pro-B-type Natriuretic Peptide/B-type Natriuretic Peptide for Heart Failure-related Events in Stable Outpatients with Cardiovascular Risk Factors. Intern Med. 2018 Sep 15;57(18):2621-2630.
Wang Y, Zhang R, Huang Y. et al. Combining the use of amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the prognosis of hospitalized heart failure patients. Clin Chim Acta. 2019 491:8-14.
